Alumis (ALMS) Expected to Announce Quarterly Earnings on Wednesday

Alumis (NASDAQ:ALMS) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($1.40) per share for the quarter.

Alumis Trading Up 0.8 %

Shares of ALMS opened at $5.17 on Monday. The stock has a fifty day moving average of $7.11 and a two-hundred day moving average of $9.69. Alumis has a fifty-two week low of $4.74 and a fifty-two week high of $13.53.

Analyst Ratings Changes

ALMS has been the subject of several research reports. Oppenheimer initiated coverage on shares of Alumis in a research note on Thursday, January 30th. They set an “outperform” rating and a $32.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. Robert W. Baird initiated coverage on shares of Alumis in a research report on Thursday, October 31st. They set an “outperform” rating and a $25.00 price target for the company. HC Wainwright decreased their price target on shares of Alumis from $26.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, Baird R W raised shares of Alumis to a “strong-buy” rating in a research report on Thursday, October 31st. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Alumis has an average rating of “Buy” and a consensus price target of $26.57.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.